^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
ArteraAI Prostate Test

Company:
ArteraAI
Type:
Laboratory Developed Test
Evidence

News

1m
Validation of an artificial intelligence-based prognostic biomarker in patients with oligometastatic Castration-Sensitive prostate cancer. (PubMed)
The ArteraAI MMAI biomarker is prognostic for OS and TTCRPC among patients with omCSPC and may predict for response to MDT. Further work is needed to validate the MMAI biomarker in a broader mCSPC cohort.
Journal • Metastases
|
ArteraAI Prostate Test
2ms
Artera’s multimodal artificial intelligence named among TIME's 2024 best inventions (Businesswire)
"Artera...announced that its MMAI platform has been named among TIME’s Best Inventions of 2024 in the medical care category. Each year, TIME honors 200 groundbreaking inventions that are making the world a better place."
Clinical
|
ArteraAI Prostate Test
2ms
Artera receives California lab license, expanding access to its ArteraAI Prostate Test (Businesswire)
"Artera...announced today it has received its California laboratory license from the California Department of Public Health (CDPH). This licensure allows Artera to offer its innovative ArteraAI Prostate Test to one of the largest healthcare markets in the United States."
Clinical
|
ArteraAI Prostate Test
2ms
Investigating the Biological Basis of Multimodal AI Predictions in Prostate Cancer Using Spatial Single-cell Proteomics (PCF 2024)
We successfully applied attention heatmaps and paired spatial proteomics data to interpret the imaging features prognostic of clinical outcomes in localized prostate cancer. Significant correlations were observed between the MMAI image feature attention values and expression of canonical tumor markers (e.g. AR and PSMA) and immune markers (e.g.
CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule)
|
ArteraAI Prostate Test
5ms
Validation of a digital pathology-based multimodal artificial intelligence (MMAI) prostate biopsy biomarker in a prospective, real-world Swedish prostate cancer (PCa) cohort treated with radical prostatectomy (ESMO 2024)
We found the prostate biopsy MMAI biomarker, previously shown to be prognostic for distant metastasis and prostate cancer-specific mortality in men getting definitive radiation, to be prognostic for post-RP endpoints: BCR and AP. This biomarker validation study using a real-world cohort further supports the use of MMAI biomarkers in men with PCa outside NA and those treated with RP.
Real-world evidence • Clinical • Real-world • Biopsy
|
ArteraAI Prostate Test
7ms
Artera Announces Three Presentations at ASCO 2024 That Demonstrate the Reliability and Depth of its AI Cancer Platform (Businesswire)
"Artera...will present three abstracts at the 2024 ASCO Annual Meeting demonstrating that its multimodal artificial intelligence (MMAI) platform provides significant prognostic value across various stages of prostate cancer and for early stage breast cancer. These studies build upon the first AI-enabled test that delivers prognostic and predictive insights for localized prostate cancer patients: ArteraAI Prostate Test...The MMAI platform can provide results to support personalized therapy by combining a patient’s unique clinical data with their pathology slides. Artera is taking a unique approach to this by applying AI to images of hematoxylin and eosin (H&E)-stained pathology slides to provide prognostic and predictive results."
Clinical data
|
ArteraAI Prostate Test
8ms
Validation of a digital pathology-based multimodal artificial intelligence model in oliogmetastatic castration-sensitive prostate cancer, including in patients from the STOMP and ORIOLE phase II randomized clinical trials. (ASCO 2024)
We have shown for the first time that the ArteraAI MMAI biomarker is prognostic for OS in patients with omCSPC. Further, MMAI appears to be predict benefit of MDT with high MMAI demonstrating a greater improvement in MFS following MDT over observation. Further work in validating these findings is warranted to allow for greater personalization in the management of patients with omCSPC.
P2 data • Clinical • Metastases
|
ArteraAI Prostate Test
9ms
Artificial intelligence Steering Testosterone deprivation Treatments in prostate cancer External-beam radiotherapy (ASTuTE) (ANZCTR)
P=N/A | N=800 | Recruiting | Sponsor: GenesisCare | Not yet recruiting ➔ Recruiting | Initiation date: Dec 2023
Enrollment open • Trial initiation date
|
ArteraAI Prostate Test
10ms
ArteraAI Announced as the First-and-Only Predictive Test for Therapy Personalization in the 2024 NCCN Guidelines for Prostate Cancer (Businesswire)
"ArteraAI...announced today its inclusion in the newly released NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer. The ArteraAI Prostate Test is the only test included for its predictive performance. The test is also the first AI-enabled predictive and prognostic test to be recommended in the guidelines for localized prostate cancer."
NCCN guideline
|
ArteraAI Prostate Test